Zerion Pharma and Hovione have teamed up and are offering potential pharma partners an end-to-end development process for Dispersome®-based formulations with capability for scale up and GMP manufacturing. The Dispersome® technology can be applied at any stage of drug discovery or drug development including in preclinical studies, first in man and replacement of existing drug formulations. By combining forces Zerion and Hovione will enable access to an innovative drug delivery platform and world class expertise in development and manufacturing, with the shortest possible development time.
Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Zerion Pharma and Hovione are offering pharma and biotech companies worldwide access to an innovative drug delivery platform combined with an unparalleled experience in development, scale up and GMP manufacturing. This unique combination provides customers with a line of sight over the entire development life cycle of oral solid dosage forms from API to commercial drug product.
AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor...
22.februar 2022 (KØBENHAVN, Danmark). Zerion Pharma A/S (ZERION), en dansk medicinalvirksomhed, har indgået et strategisk partnerskab med HOVIONE, en førende global udviklings- og kontraktproducent for at accelerere kommercialiseringen af ZERIONs Dispersome®-teknologi, der benyttes...
February 22, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION), a Danish drug development company, is pleased to announce today to have entered into a strategic partnership with HOVIONE, a leading global specialist integrated development and contract manufacturer to accelerate the commercialization...
"We are extremely pleased to have entered into this partnership with ZERION whom we recognize as a very innovative company in the field of oral drug formulations. ZERION´s proprietary Dispersome® technology builds on a new concept of increasing drug solubility by using natural protein-based excipients. I foresee that this will become a valuable component in HOVIONE’s leading amorphous solid dispersion technology platform."
